Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Shares Issued (2020 - 2025)

Historic Shares Issued for Janux Therapeutics (JANX) over the last 5 years, with Q1 2025 value amounting to $901000.0.

  • Janux Therapeutics' Shares Issued fell 4562.46% to $901000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $4.1 million, marking a year-over-year increase of 2783.44%. This contributed to the annual value of $204.2 million for FY2021, which is N/A changed from last year.
  • As of Q1 2025, Janux Therapeutics' Shares Issued stood at $901000.0, which was down 4562.46% from $1.7 million recorded in Q1 2024.
  • Over the past 5 years, Janux Therapeutics' Shares Issued peaked at $1.7 million during Q1 2024, and registered a low of -$843000.0 during Q3 2021.
  • Over the past 4 years, Janux Therapeutics' median Shares Issued value was $1.2 million (recorded in 2023), while the average stood at $823750.0.
  • As far as peak fluctuations go, Janux Therapeutics' Shares Issued surged by 487.34% in 2024, and later crashed by 4562.46% in 2025.
  • Quarter analysis of 4 years shows Janux Therapeutics' Shares Issued stood at -$843000.0 in 2021, then surged by 287.43% to $1.6 million in 2023, then increased by 4.87% to $1.7 million in 2024, then plummeted by 45.62% to $901000.0 in 2025.
  • Its Shares Issued was $901000.0 in Q1 2025, compared to $1.7 million in Q1 2024 and $1.6 million in Q1 2023.